Martin Huber
2023 - Mersana Therapeutics
In 2023, Martin Huber earned a total compensation of $2.6M as President and Chief Executive Officer at Mersana Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $110,466 |
|---|---|
| Option Awards | $1,133,300 |
| Salary | $194,311 |
| Stock Awards | $880,440 |
| Other | $282,733 |
| Total | $2,601,249 |
Huber received $1.1M in option awards, accounting for 44% of the total pay in 2023.
Huber also received $110.5K in non-equity incentive plan, $194.3K in salary, $880.4K in stock awards and $282.7K in other compensation.
Rankings
In 2023, Martin Huber's compensation ranked 369th out of 2,878 executives tracked by ExecPay. In other words, Huber earned more than 87.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 369 out of 2,878 | 87th |
Division Manufacturing | 212 out of 1,582 | 87th |
Major group Chemicals And Allied Products | 148 out of 891 | 83rd |
Industry group Drugs | 145 out of 854 | 83rd |
Industry Pharmaceutical Preparations | 88 out of 614 | 86th |
Source: SEC filing on April 26, 2024.
Huber's colleagues
We found six more compensation records of executives who worked with Martin Huber at Mersana Therapeutics in 2023.
2023
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
2023
Arvin Yang
Mersana Therapeutics
Chief Medical Officer
2023
Brian DeSchuytner
Mersana Therapeutics
Chief Financial Officer
2023
Timothy Lowinger
Mersana Therapeutics
Senior Vice President, Chief Science and Technology Officer
2023
Alejandra Carvajal
Mersana Therapeutics
Chief Legal Officer
2023
Mohan Bala
Mersana Therapeutics
Senior Vice President, Chief Development Officer
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Xilio Therapeutics CEO René Russo's 2023 pay jumps 36% to $3M
April 25, 2024
Xilio Therapeutics CEO René Russo's 2022 pay falls 60% to $2.2M
April 25, 2023
Xilio Therapeutics CEO René Russo's 2021 pay jumps 118% to $5.5M
April 26, 2022